https://beigenevirtualexperience.com/
BeiGene has one of the world’s largest oncology research teams and a pipeline with the potential to address 80% of the world’s cancers by type. BeiGene’s small molecule inhibitor of BTK, BRUKINSA, is approved in more than 65 markets across the world. One of BeiGene’s investigational medicines is Tislelizumab, a humanized monoclonal antibody directed against the immune checkpoint receptor PD-1, and is being investigated in multiple solid tumors and hematologic malignancies.